Pegylated Liposomal Doxorubicin Versus Gemcitabine in Recurrent Ovarian Cancer
Posted: Monday, December 21, 2020
Results from a retrospective study published in The Journal of Obstetrics & Gynaecology Research found that pegylated liposomal doxorubicin therapy, a second-line chemotherapy treatment, may be more effective than gemcitabine therapy in patients with ovarian cancer who have had at least three prior treatment regimens. Hiroyuki Fujiwara, MD, PhD, of Jichi Medical University in Japan, and colleagues found pegylated liposomal doxorubicin therapy to be well tolerated.
The single-center study included 78 patients with platinum-resistant recurrent ovarian cancer. Patients had undergone at least two cycles of pegylated liposomal doxorubicin therapy between July 2009 and March 2017. The overall disease control rate was 53.8%; the disease control rate by the previous number of regimens was 53.8% for one, 48.6% for two, 63.6% for three, and 66.7% for four or more. The overall response rate was 19.2%. The most common adverse events of at least grade 2 included hand-foot syndrome (25.6%), stomatitis (25.6%), and liver dysfunction (2.6%). Grade 3 or 4 neutropenia occurred in 56% of participants, and 12.8% experienced grade 3 or 4 anemia.
Reported data regarding gemcitabine treatment were to compare the safety and efficacy of gemcitabine versus pegylated liposomal doxorubicin treatment. The disease response rate was substantially higher among patients who had previously undergone at least three treatment regimens before later receiving pegylated liposomal doxorubicin (64.7%) than those who later received gemcitabine (30.8%; P = .037).
Disclosure: The study authors reported no conflicts of interest.